Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary thyroid lymphoma: The two ends of the spectrum.
Triantafillou E, Papadakis G, Tzaida O, Papazian M, Megalakaki A, Moustakas K, Keramidas I, Kaltzidou V, Tertipi A, Pappas A. Triantafillou E, et al. Among authors: megalakaki a. J BUON. 2015 Jul-Aug;20(4):1164-8. J BUON. 2015. PMID: 26416071 Free article.
Significance of the detection of paroxysmal nocturnal hemoglobinuria clones in patients with multiple myeloma undergoing autologous stem cell transplantation.
Chatziantoniou V, Alexia S, Konstantopoulos K, Repousis P, Megalakaki A, Kotsopoulou M, Kylidou P, Vassilakopoulos T, Angelopoulou MK. Chatziantoniou V, et al. Among authors: megalakaki a. Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):150-9. doi: 10.1016/j.hemonc.2015.06.008. Epub 2015 Jul 9. Hematol Oncol Stem Cell Ther. 2015. PMID: 26183672 Free article.
Castleman disease and adenocarcinoma.
Megalakaki A, Evmorfiadis I, Stamouli M, Zakopoulou N, Iacovidou I. Megalakaki A, et al. J BUON. 2011 Oct-Dec;16(4):781-2. J BUON. 2011. PMID: 22331742 No abstract available.
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Katodritou E, et al. Among authors: megalakaki a. Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Ann Hematol. 2018. PMID: 29756171 Free PMC article.
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Katodritou E, et al. Among authors: megalakaki a. Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8. Ann Hematol. 2018. PMID: 29943159 Free PMC article.
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Papageorgiou SG, Kotsianidis I, Bouchla A, Symeonidis A, Galanopoulos A, Viniou NA, Hatzimichael E, Vassilakopoulos TP, Gogos D, Megalakaki A, Zikos P, Diamantopoulos P, Kourakli A, Giannoulia P, Papoutselis M, Poulakidas E, Arapaki M, Vardi A, Anagnostopoulos A, Mparmparousi D, Papaioannou M, Bouronikou E, Dimou M, Papadaki H, Panayiotidis P, Pappa V. Papageorgiou SG, et al. Among authors: megalakaki a. Ther Adv Hematol. 2020 Dec 8;11:2040620720966121. doi: 10.1177/2040620720966121. eCollection 2020. Ther Adv Hematol. 2020. PMID: 33343854 Free PMC article.
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.
Diamantopoulos PT, Solomou E, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Vassilakopoulos T, Dimou M, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. Diamantopoulos PT, et al. Among authors: megalakaki a. Am J Hematol. 2023 May;98(5):E119-E122. doi: 10.1002/ajh.26886. Epub 2023 Mar 1. Am J Hematol. 2023. PMID: 36808739 Free article. No abstract available.
20 results